Stock Analiz

Dianthus Therapeutics, Inc. (DNTH) financials: revenue, earnings and cash flow

Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

Net income in fiscal 2025 was -$162M, a net margin of -7973.3%; the best year in this period was 2016 with -$9M.

Over the twelve months to September 30, 2026, revenue was $3M and net income -$202M.

Free cash flow was -$129M in fiscal 2025 and positive in 0 of the 10 years shown.

The diluted share count rose 1755196% over the period (dilution).

Revenue, profit and cash flow by year

Revenue
2016: $020162017: $020172018: $020182019: $020192023: $3M20232024: $6M20242025: $2M2025$2M
Net income
2016: -$9M162017: -$35M172018: -$58M182019: -$77M192020: -$75M202021: -$71M212022: -$28M222023: -$44M232024: -$85M242025: -$162M25-$162M
Free cash flow
2016: -$7M162017: -$24M172018: -$50M182019: -$60M192020: -$64M202021: -$61M212022: -$29M222023: -$37M232024: -$78M242025: -$129M25-$129M
EPS (diluted)
2016: $-4424.57162017: $-1298.51172018: $-212.57182019: $-140.58192020: $-116.13202021: $-87.61212022: $-32.57222023: $-8.45232024: $-2.55242025: $-4.2025$-4.20

Income statement

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$3M$2M$6M$3M———$0$0$0$0
Gross profit———————————
Operating income-$236M-$178M-$102M-$48M-$30M-$75M-$79M-$83M-$60M-$36M-$9M
Net income-$202M-$162M-$85M-$44M-$28M-$71M-$75M-$77M-$58M-$35M-$9M
EPS (diluted)$-4.08$-4.20$-2.55$-8.45$-32.57$-87.61$-116.13$-140.58$-212.57$-1298.51$-4424.57
R&D$189M$146M$83M$33M$29M$47M$51M$59M$41M$28M$6M
Revenue growth—−67.3%+120.6%————————

Cash flow

Fiscal yearTTM2025202420232022202120202019201820172016
Operating cash flow-$175M-$129M-$78M-$37M-$29M-$60M-$64M-$57M-$42M-$22M-$7M
Capital spending-$697000-$213000-$105000-$110000-$314000-$1M-$400000-$3M-$8M-$2M-$139000
Free cash flow-$176M-$129M-$78M-$37M-$29M-$61M-$64M-$60M-$50M-$24M-$7M
Dividends paid—$0$0$0$0$0$0$0$0$0$0
Buybacks———————————
Stock-based pay$41M$23M$13M$3M$2M$10M$10M$10M$11M$2M$662000

Balance sheet

Fiscal yearTTM2025202420232022202120202019201820172016
Cash—$404M$275M$174M$75M$177M$149M$146M$143M$51M$5M
Debt—$1M$1M$585000$30M$0$0$0$0$0—
Equity—$493M$352M$169M-$44M-$17M$144M$141M$146M-$42M-$9M
Total assets—$531M$374M$179M$83M$190M$162M$162M$157M$54M—
Shares (diluted)57M39M33M5M1M1M1M1M0M0M0M

Margins and returns

Fiscal yearTTM2025202420232022202120202019201820172016
Gross margin———————————
Operating margin-8683.9%-8739.3%-1633.7%-1704.7%———————
Net margin-7436.5%-7973.3%-1362.8%-1541.2%———————
FCF margin-6469.9%-6349.4%-1255.6%-1308.2%———————
ROIC—-28.4%-22.7%-22.5%——-43.2%-46.4%-32.5%——
ROE—-32.9%-24.1%-25.8%64.2%412.4%-52.1%-54.4%-39.5%84.3%106.3%

Frequently asked questions

What is Dianthus Therapeutics’s annual revenue?

$2M in fiscal 2025 and $3M over the twelve months to September 30, 2026.

How much profit does Dianthus Therapeutics make?

Net income was -$162M in fiscal 2025 (net margin -7973.3%).

Is Dianthus Therapeutics’s revenue growing?

No: revenue fell 67.3% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.